公开(公告)号：US11266762B2

公开(公告)日：2022-03-08

申请号：US16294698

申请日：2019-03-06

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Alistair Simpson Irvine ,  Philippe Paul Saudan

IPC分类号： A61L24/10 ,  A61L27/22 ,  A61L27/54

摘要： Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

公开(公告)号：US20190275197A1

公开(公告)日：2019-09-12

申请号：US16294698

申请日：2019-03-06

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Alistair Simpson Irvine ,  Philippe Paul Saudan

IPC分类号： A61L24/10

摘要： Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.

公开(公告)号：US20220331110A1

公开(公告)日：2022-10-20

申请号：US17762223

申请日：2020-09-21

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Philippe Paul Saudan ,  Alistair Simpson Irvine

IPC分类号： A61F2/28 ,  A61L27/54 ,  A61F2/44 ,  A61L27/48 ,  A61L27/22 ,  A61F2/46

摘要： The invention concerns a bone graft material for use in a spinal fusion method, wherein the material comprises i) a composition for forming a matrix, comprising at least a first matrix material precursor component and a second matrix material precursor component, capable of forming a matrix by crosslinking of the precursor components under appropriate conditions; and ii) a bioactive factor, which is biologically active to stimulate bone formation between two vertebrae, and for effecting or supporting spinal fusion; wherein the spinal fusion method comprises the steps of applying a cage in between the two vertebrae, which is not pre-filled with the bone graft material; and subsequently applying the bone graft material adjacent to and/or into the cage, such that essentially the entire remaining volume between the two vertebrae is filled with the bone graft material. The invention allows for ease of use while forming a more homogeneous matrix.

公开(公告)号：US20220202987A1

公开(公告)日：2022-06-30

申请号：US17671463

申请日：2022-02-14

申请人： Kuros Biosurgery AG

发明人： Lorenz Vogt ,  Alistair Simpson Irvine ,  Philippe Paul Saudan

IPC分类号： A61L24/10 ,  A61L27/54

摘要： Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.